Development of a steroidogenic factor 1/Cre transgenic mouse line

Nathan C. Bingham, Sunita Verma-Kurvari, Luis F. Parada, Keith L. Parker

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

The Cre-loxP strategy provides an approach to disrupt genes in specific tissues and/or cell types, circumventing lethality associated with global knockouts or secondary effects due to gene inactivation at other sites. A critical component is the development of transgenes that target Cre expression to specific cell types. Here, we describe the use of bacterial artificial chromosome (BAC) transgenesis to target Cre expression to tissues that express steroidogenic factor 1 (SF-1, officially designated Nr5a1). Consistent with the SF-1 expression pattern, the SF-1 BAC directed Cre expression to the somatic cells of the gonads, the adrenal cortex, the anterior pituitary, the spleen, and the ventromedial hypothalamic nucleus. This transgene provides a powerful tool to inactivate genes of interest in these tissues.

Original languageEnglish (US)
Pages (from-to)419-424
Number of pages6
JournalGenesis
Volume44
Issue number9
DOIs
StatePublished - Sep 2006

Fingerprint

Steroidogenic Factor 1
Transgenic Mice
Bacterial Artificial Chromosomes
Transgenes
Ventromedial Hypothalamic Nucleus
Gene Transfer Techniques
Adrenal Cortex
Gonads
Gene Silencing
Genes
Spleen

Keywords

  • Adrenal
  • Cre
  • Gonad
  • Steroidogenic factor 1
  • VMH

ASJC Scopus subject areas

  • Genetics

Cite this

Bingham, N. C., Verma-Kurvari, S., Parada, L. F., & Parker, K. L. (2006). Development of a steroidogenic factor 1/Cre transgenic mouse line. Genesis, 44(9), 419-424. https://doi.org/10.1002/dvg.20231

Development of a steroidogenic factor 1/Cre transgenic mouse line. / Bingham, Nathan C.; Verma-Kurvari, Sunita; Parada, Luis F.; Parker, Keith L.

In: Genesis, Vol. 44, No. 9, 09.2006, p. 419-424.

Research output: Contribution to journalArticle

Bingham, NC, Verma-Kurvari, S, Parada, LF & Parker, KL 2006, 'Development of a steroidogenic factor 1/Cre transgenic mouse line', Genesis, vol. 44, no. 9, pp. 419-424. https://doi.org/10.1002/dvg.20231
Bingham NC, Verma-Kurvari S, Parada LF, Parker KL. Development of a steroidogenic factor 1/Cre transgenic mouse line. Genesis. 2006 Sep;44(9):419-424. https://doi.org/10.1002/dvg.20231
Bingham, Nathan C. ; Verma-Kurvari, Sunita ; Parada, Luis F. ; Parker, Keith L. / Development of a steroidogenic factor 1/Cre transgenic mouse line. In: Genesis. 2006 ; Vol. 44, No. 9. pp. 419-424.
@article{bf4463758a22421eb79edb0ba27b2505,
title = "Development of a steroidogenic factor 1/Cre transgenic mouse line",
abstract = "The Cre-loxP strategy provides an approach to disrupt genes in specific tissues and/or cell types, circumventing lethality associated with global knockouts or secondary effects due to gene inactivation at other sites. A critical component is the development of transgenes that target Cre expression to specific cell types. Here, we describe the use of bacterial artificial chromosome (BAC) transgenesis to target Cre expression to tissues that express steroidogenic factor 1 (SF-1, officially designated Nr5a1). Consistent with the SF-1 expression pattern, the SF-1 BAC directed Cre expression to the somatic cells of the gonads, the adrenal cortex, the anterior pituitary, the spleen, and the ventromedial hypothalamic nucleus. This transgene provides a powerful tool to inactivate genes of interest in these tissues.",
keywords = "Adrenal, Cre, Gonad, Steroidogenic factor 1, VMH",
author = "Bingham, {Nathan C.} and Sunita Verma-Kurvari and Parada, {Luis F.} and Parker, {Keith L.}",
year = "2006",
month = "9",
doi = "10.1002/dvg.20231",
language = "English (US)",
volume = "44",
pages = "419--424",
journal = "Genesis",
issn = "1526-954X",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Development of a steroidogenic factor 1/Cre transgenic mouse line

AU - Bingham, Nathan C.

AU - Verma-Kurvari, Sunita

AU - Parada, Luis F.

AU - Parker, Keith L.

PY - 2006/9

Y1 - 2006/9

N2 - The Cre-loxP strategy provides an approach to disrupt genes in specific tissues and/or cell types, circumventing lethality associated with global knockouts or secondary effects due to gene inactivation at other sites. A critical component is the development of transgenes that target Cre expression to specific cell types. Here, we describe the use of bacterial artificial chromosome (BAC) transgenesis to target Cre expression to tissues that express steroidogenic factor 1 (SF-1, officially designated Nr5a1). Consistent with the SF-1 expression pattern, the SF-1 BAC directed Cre expression to the somatic cells of the gonads, the adrenal cortex, the anterior pituitary, the spleen, and the ventromedial hypothalamic nucleus. This transgene provides a powerful tool to inactivate genes of interest in these tissues.

AB - The Cre-loxP strategy provides an approach to disrupt genes in specific tissues and/or cell types, circumventing lethality associated with global knockouts or secondary effects due to gene inactivation at other sites. A critical component is the development of transgenes that target Cre expression to specific cell types. Here, we describe the use of bacterial artificial chromosome (BAC) transgenesis to target Cre expression to tissues that express steroidogenic factor 1 (SF-1, officially designated Nr5a1). Consistent with the SF-1 expression pattern, the SF-1 BAC directed Cre expression to the somatic cells of the gonads, the adrenal cortex, the anterior pituitary, the spleen, and the ventromedial hypothalamic nucleus. This transgene provides a powerful tool to inactivate genes of interest in these tissues.

KW - Adrenal

KW - Cre

KW - Gonad

KW - Steroidogenic factor 1

KW - VMH

UR - http://www.scopus.com/inward/record.url?scp=33749007685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749007685&partnerID=8YFLogxK

U2 - 10.1002/dvg.20231

DO - 10.1002/dvg.20231

M3 - Article

C2 - 16937416

AN - SCOPUS:33749007685

VL - 44

SP - 419

EP - 424

JO - Genesis

JF - Genesis

SN - 1526-954X

IS - 9

ER -